Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selectis HealthGBCS -1.22%41 EV-to-EBITDA is 3.28 as of Aug. 08, 2026, which is 82% below its 10-year median of 17.84. GuruFocus rates GBCS with a GF Score™ of 41/100 and a GF Value™ of $2.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 510 Healthcare Providers & Services companies, Selectis Health ranks better than 93.33% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Selectis Health's enterprise value is $33.25 Mil.
Selectis Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $10.13 Mil. Therefore, Selectis Health's EV-to-EBITDA for today is 3.28.
The historical rank and industry rank for Selectis Health's EV-to-EBITDA or its related term are showing as below:
GBCS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -465.21 Med: 17.84 Max: 67.5
Current: 3.28
During the past 13 years, the highest EV-to-EBITDA of Selectis Health was 67.50. The lowest was -465.21. And the median was 17.84.
GBCS's EV-to-EBITDA is ranked better than 93.33% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs GBCS: 3.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Selectis Health (OTCPK:GBCS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Selectis Health's PE Ratio (TTM) for today is calculated as:
Selectis Health's share price for today is $5.41325.
Selectis Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Selectis Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Selectis Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selectis Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Selectis Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Selectis Health's EV-to-EBITDA falls into.
Selectis Health's current Enterprise Value is $33.25 Mil.
Selectis Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selectis Health (GBCS) has a EV-to-EBITDA of 3.28 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Selectis Health. This is 82% below median its historical median of 17.84. According to the industry distribution chart, Selectis Health ranks #34 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 6.7%.
Is Selectis Health's EV-to-EBITDA too high?
Selectis Health's current EV-to-EBITDA of 3.28 is 82% below median its 10-year median of 17.84. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Selectis Health's value of 3.28 is 70% below this industry median. Based on the distribution chart, Selectis Health ranks #34 out of 510 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Selectis Health has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selectis Health's EV-to-EBITDA compare to ADIA and CCM?
According to the Healthcare Providers & Services industry distribution chart, Selectis Health ranks #34 out of 510 companies for EV-to-EBITDA. This places Selectis Health in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.92. Selectis Health's value of 3.28 is 70% below this benchmark. While the company's 10-year median is 17.84 vs. the industry median of 10.92, Selectis Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selectis Health's current EV-to-EBITDA of 3.28 is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Selectis Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selectis Health's current EV-to-EBITDA is 3.28, which is 82% below median its own 10-year median of 17.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selectis Health stock overvalued right now?
Based on GuruFocus' analysis, Selectis Health (GBCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.15, compared to a current price of $5.41 — trading 151.8% above its estimated fair value. The current EV-to-EBITDA is 3.28, which is 82% below median its 10-year median of 17.84 and 70% below the Healthcare Providers & Services industry median of 10.92. Selectis Health's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Selectis Health (GBCS), the current EV-to-EBITDA is 3.28 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selectis Health (GBCS) Overvalued in 2026?
Based on GuruFocus' analysis, Selectis Health stock appears to be overvalued.
The current stock price of $5.41 is trading 151.8% above its estimated GF Value™ of $2.15.
GuruFocus considers Selectis Health to be Significantly Overvalued.
Key valuation signals for GBCS:
EV-to-EBITDA: 3.28 (82% below median its 10-year median of 17.84)
GF Value™: $2.15 vs. price of $5.41 (151.8% above fair value)
Industry Position: 70% below the Healthcare Providers & Services median (#34 of 510)
No single metric tells the full story. See the GBCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selectis Health Inc owns and operates medical care facilities in the healthcare industry. The company acquires, develops, leases, and manages healthcare real estate and provides healthcare operations through its wholly-owned subsidiaries. The portfolio is comprised of investments in the following healthcare operations: (i) senior housing (including independent and assisted living) and (ii) post-acute/skilled nursing. It makes investments within the healthcare operations using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008, which represents investments in senior housing operations, and (vi) owning healthcare operations.
41GF Score
Get the complete analysis for GBCS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GBCS has been successfully added to your 
